ArthroCare (NASDAQ: ARTC) is a United States-based public company in the field of medical devices.[1] The prime focus of the company is soft tissue repair and ablation technology in the medical areas of larger joints (knee, hip, and shoulder), spine as well as ENT.

Controversies

In 2008, several class actions were filed against ArthroCare, alleging that ArthroCare issued materially false and misleading statements and failed to disclose some adverse facts. In 2012, a settlement of $74 million was approved.[2]

References

  1. ↑ Dealbook (18 August 2009). "One Equity Partners has signed an agreement with ArthroCare that will provide the latter with a $75 million infusion". The New York Times. Retrieved 2011-04-01.
  2. ↑ "Class Action Lawsuit Against ArthroCare". Archived from the original on 2013-06-19.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.